# About Pharmacy Sermorelin: An Editorial Research Record | Sermorelin

> Pharmacy Sermorelin is an independent editorial project publishing cited summaries of the sermorelin research literature. Not a clinic, not a pharmacy, nothing sold.

An independent editorial project that reads the published sermorelin literature straight and logs it as a record.

## What this project is

Pharmacy Sermorelin is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The 'pharmacy' in the name is editorial framing — the register of a compounding-record or research console, the position this publisher takes relative to the literature. It is not a claim that this site is a pharmacy, dispenses anything, or fills a prescription. Nothing here is for sale, and no order can be placed.

## How the record is built

The site is organized as a terminal-style research record. Each finding is logged with its source, its study population and route, and a tier flag distinguishing confirmed human and pharmacokinetic data from the angle and supporting signals (the regenerative, cardiac, and in-silico oncology findings). Quantitative claims — the ~10-12 minute plasma half-life, the +117% IGF-1 figure from the GHRH-analog cognition trial, the 30 mcg/kg/day pediatric dose — resolve to a numbered citation on the references page [3][11][4].

The editorial stance is deliberately conservative about a compound whose marketing runs ahead of its evidence. Where the strongest data come from the related analog tesamorelin rather than native sermorelin, we say so. Where a striking result is computational or preclinical, we tag it as a hypothesis. The record is built to keep those distinctions visible.

## Sermorelin acetate, in brief

For readers arriving fresh: sermorelin acetate is the amidated GHRH(1-29) salt — a 29-amino-acid pituitary GH secretagogue, formerly FDA-approved for pediatric GH deficiency, withdrawn from the US market in 2008 for commercial reasons, and now compounded under FDA's interim Section 503A policy [1]. The full pharmacology lives on the [sermorelin mechanism of action](/mechanism) page; this page is only about who publishes the record and how.

## What we do not claim

We do not diagnose, treat, or advise. We do not recommend doses for any person. We do not endorse sermorelin or any other compound, and we do not assert that the regenerative or oncology-frontier signals represent established clinical benefit. The references page exposes every source so any claim here can be checked against the primary literature.

---

A near-black terminal record of the sermorelin literature — GHRH(1-29) traced from receptor to IGF-1, each datum logged to its source and tagged by tier, with the confirmed human data kept apart from the regenerative and in-silico frontier signals; no clinic behind the console and nothing here dispensed or sold.